Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Melanoma is a highly aggressive form of skin cancer that frequently metastasizes to vital organs, where it is often difficult to treat with traditional therapies such as surgery and radiation. In such cases of metastatic disease, immunotherapy has emerged in recent years as an exciting treatment option for melanoma patients. Despite unprecedented successes with immune therapy in the clinic, many patients still experience disease relapse, and others fail to respond at all, thus highlighting the need to better understand factors that influence the efficacy of antitumor immune responses. At the heart of antitumor immunity are dendritic cells (DCs), an innate population of cells that function as critical regulators of immune tolerance and activation. As such, DCs have the potential to serve as important targets and delivery agents of cancer immunotherapies. Even immunotherapies that do not directly target or employ DCs, such as checkpoint blockade therapy and adoptive cell transfer therapy, are likely to rely on DCs that shape the quality of therapy-associated antitumor immunity. Therefore, understanding factors that regulate the function of tumor-associated DCs is critical for optimizing both current and future immunotherapeutic strategies for treating melanoma. To this end, this review focuses on advances in our understanding of DC function in the context of melanoma, with particular emphasis on (1) the role of immunogenic cell death in eliciting tumor-associated DC activation, (2) immunosuppression of DC function by melanoma-associated factors in the tumor microenvironment, (3) metabolic constraints on the activation of tumor-associated DCs, and (4) the role of the microbiome in shaping the immunogenicity of DCs and the overall quality of anti-melanoma immune responses they mediate. Additionally, this review highlights novel DC-based immunotherapies for melanoma that are emerging from recent progress in each of these areas of investigation, and it discusses current issues and questions that will need to be addressed in future studies aimed at optimizing the function of melanoma-associated DCs and the antitumor immune responses they direct against this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“In the B16-SIY melanoma model, the success of α-PD-L1 Ab therapy was shown to rely on the presence within the intestinal microbiota of Bifidobacterium species that enhance the antitumor effects of therapy (195).”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“In other work investigating microbial influences on checkpoint blockade therapy, pretreatment of mice with a cocktail of broad-spectrum antibiotics blocked the efficacy of α-CTLA-4 Ab therapy for established Ret murine melanomas (196).”
BackgroundGut microbiota, metabolites and host immunity
Rooks, M. G., & Garrett, W. S. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.42 · Cited by 3,409
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 3×
“Oxilaplatin B16-F10 Calreticulin, ATP, high-mobility group box 1 (HMGB1) Yes (68, 69)”
BackgroundSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819 · cited 1×
“Other next-generation vaccination approaches currently being explored include immunization with tumor-specific neoantigens (either alone or loaded onto DC) that promote responses against mutated tumor-specific epitopes (44–46) as well as maneuvers that induce local or systemic activation of endogenous, tumor Ag-presen…”
BackgroundCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 3×
“Doxorubicin B16-F10 Not determined Yes (67)”
BackgroundChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation
Krawczyk, C. M., Holowka, T., Sun, J., Blagih, J., Amiel, E., DeBerardinis, R. J., Cross, J. R., Jung, E., Thompson, C. B., Jones, R. G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-249540 · Cited by 1,246
Everts, B., Amiel, E., Huang, S. C.-C., Smith, A. M., Chang, C.-H., Lam, W. Y., Redmann, V., Freitas, T. C., Blagih, J., van der Windt, G. J. W., et al. (2014) · Nature Immunology · doi:10.1038/ni.2833 · Cited by 1,064
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“Additionally, their induction of type I IFN secretion by dying tumor cells can also lead to autocrine signals that trigger release of chemokines such as CXCL10 that promote recruitment of immune cell populations to the tumor (53, 56).”
BackgroundDubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Together, these insights will be important for the optimization of strategies to manipulate the gut microbiome in ways that enhance antitumor immune reactivity while also minimizing adverse events such as therapy-associated colitis (202).”
BackgroundMcArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933 · cited 2×
“In a murine model of ovarian cancer, this approach reduced triglyceride levels in tumor-associated DC, augmented the activation of tumor Ag-specific T cells, and improved tumor immune control and overall survival of tumor-bearing mice (168).”
BackgroundMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883 · cited 1×
“Additionally, as evidence is accumulating that the gut microbiome also influences immunometabolism (200) as well as the metabolism and antitumor activity of chemotherapeutic drugs (201), future studies are needed to investigate how particular microbial species and their metabolites regulate chemotherapy-driven ICD and…”
BackgroundDendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · cited 1×
“Likewise, tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO)-producing regulatory pDC recovered from melanoma-draining lymph nodes is associated both with suppression of CD8+ T cells (129) and with activation of CD4+ Tregs (130).”
BackgroundOncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · cited 8×
“Context of Melanoma In melanoma, metabolic rewiring for glycolysis may be driven by multiple signaling pathways, including BRAF-driven MAPK hyperactivation that negatively regulates OXPHOS (152) and PI3K/AKT/mTOR/HIF1α signaling that positively regulates glycolysis (153).”
BackgroundInfluentialTumor-derived lactic acid modulates dendritic cell activation and antigen expression
Gottfried, E., Kunz-Schughart, L. A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A., & Kreutz, M. (2006) · Blood · doi:10.1182/blood-2005-05-1795 · Cited by 729
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
The role of the microbiome in cancer development and therapy
Bhatt, A. P., Redinbo, M. R., & Bultman, S. J. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21398 · Cited by 653 · cited 1×
“Antitumor immunity to Melanoma As data have emerged demonstrating that the microbiota and dysbiosis play significant roles in both cancer progression and the efficacy of anticancer therapies (190), there has been considerable interest in understanding how the microbiome regulates”
BackgroundCancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595 · cited 1×
“Although the mechanism by which lactic acid influences tumor-associated DC function has yet to be elucidated, there is speculation that altered membrane transport in the lactate-rich tumor microenvironment might contribute to its suppressive effect (160, 161).”
BackgroundPaulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · cited 1×
“Associated immunity to Melanoma The first study to report microbial influences on the outcome of immune therapy for cancer demonstrated that the therapeutic benefit of total body irradiation prior to adoptive T cell transfer arises in part from activation of the innate immune system following radiation-induced damage…”
BackgroundCommitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells
Everts, B., Amiel, E., van der Windt, G. J. W., Freitas, T. C., Chott, R., Yarasheski, K. E., Pearce, E. L., & Pearce, E. J. (2012) · Blood · doi:10.1182/blood-2012-03-419747 · Cited by 532 · cited 1×
“Long-term commitment to glycolytic metabolism in activated DC then fuels ATP production and survival in the face of decreasing mitochondrial metabolism, which results from OXPHOS inhibition by nitric oxide in inflammatory DC (147) and from autocrine type I IFN induction of the HIF1α transcription factor that blocks mi…”
BackgroundChemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452 · cited 1×
“These include cell surface calreticulin and other endoplasmic reticulum (ER) chaperones exposed following the unfolded protein response, autophagy-mediated or conventional secretion of ATP, interleukin-1β (IL-1β) secretion as a result of inflammasome signaling, release of high-mobility group box 1 (HMGB1), and cell su…”
BackgroundAdenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430 · cited 2×
“Pharmacological antagonists of the A2B receptor block the effects of adenosine on DC differentiation in vitro, and DC from both A2A and A2B receptor knockout mice are resistant to the suppressive effects of adenosine (176, 177).”
BackgroundSpisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343 · cited 1×
“Others have reported that immature tumor-infiltrating DC isolated from B16-F0 tumors are refractory to ex vivo stimulation with a cocktail of maturation stimuli but can be induced to undergo maturation following stimulation in the presence of an anti-IL-10R neutralizing antibody (112).”
BackgroundIntegrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340
Oxidized lipids block antigen cross-presentation by dendritic cells in cancer
Cao, W., Ramakrishnan, R., Tuyrin, V. A., Veglia, F., Condamine, T., Amoscato, A., Mohammadyani, D., Johnson, J. J., Min Zhang, L., Klein-Seetharaman, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302801 · Cited by 302 · cited 1×
“Subsequent studies revealed that lipid accumulation in tumor-associated DC defective in cross-presentation resulted from an increase in polyunsaturated fatty acids, particularly linoleic acid and to a lesser extent arachidonic acid, and that DC isolated from tumor-bearing mice or exposed to tumor explant supernatants…”
BackgroundGarg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200 · cited 1×
“Many of these approaches have been incorporated into DC vaccination setups and are currently being assessed in clinical trials for prostate cancer, ovarian cancer, and head and neck squamous cell carcinoma (83).”
BackgroundCheng, M., Qian, L., Shen, G., Bian, G., Xu, T., Xu, W., Shen, G., & Hu, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2462 · Cited by 182
Wang, T., Ge, Y., Xiao, M., Lopez‐Coral, A., Azuma, R., Somasundaram, R., Zhang, G., Wei, Z., Xu, X., Rauscher, F. J., et al. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01005.x · Cited by 69 · cited 1×
“Alternatively, macrophages capable of suppressing CD4+ and CD8+ T cell proliferation have been differentiated from monocytes cultured in conditioned media from both metastatic and non-metastatic human melanoma cell lines (94), and IL-10, which can be secreted at high levels by melanomas (95), has been shown to promote…”
BackgroundMartin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response
Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136045 · Cited by 32
Cited by
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Self-citationImmunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Metadata
- Authors
- Hargadon, K. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-20
- Volume
- 8
- Pages
- 1594-1594
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2768511098
- Cited by
- 67
- References
- 46
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.